Incyte slides as investors digest updated INCA033989 (mutCALR) data and a cautious analyst take

Incyte Corporation (INCY) is down 6.0% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to investor interpretation of updated clinical results for INCA033989 (a mutant CALR-targeted antibody) presented around the European Hematology Association (EHA) 2026 timeframe, alongside renewed focus on a cautious sell-side view that framed parts of the update as incrementally less impressive versus prior snapshots. While the company highlighted rapid responses and a manageable safety profile, the stock likely reacted to perceived efficacy “give-back” in larger datasets and the reminder that key outcomes still need confirmation in registrational studies.

Details:

Incyte shared updated Phase 1 data for INCA033989 in essential thrombocythemia (ET) and myelofibrosis (MF), highlighting rapid and durable responses and reductions in mutant CALR variant allele frequency in many evaluable patients.

In ET, the company highlighted an 87% hematologic response rate with 70% complete responses, with responses described as rapid (median ~2 weeks) and durable (median response duration ~23 weeks).

In MF, the company highlighted meaningful spleen volume reductions, including best responses with ~55% achieving SVR25 and ~39% achieving SVR35 in the presented dataset.

A major bank reiterated an Underperform stance and pointed to lower efficacy measures in larger patient groups and softer MF metrics versus earlier reads as a potential overhang on sentiment.

Sources:

Incyte, Investing.com, EHA Congress Library

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$INCY Insider Trading Activity

$INCY insiders have traded $INCY stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales.

Here’s a breakdown of recent trading of $INCY stock by insiders over the last 6 months:

MICHAEL JAMES MORRISSEY (EVP, Head of Tech. Operations) has made 0 purchases and 3 sales selling 58,331 shares for an estimated $5,675,001.
PABLO J CAGNONI (President, Global Head of R&D) has made 0 purchases and 3 sales selling 56,002 shares for an estimated $5,444,331.
STEVEN H STEIN (EVP & Chief Medical Officer) sold 15,634 shares for an estimated $1,589,977
MOHAMED KHAIRIE ISSA (EVP, Head of US Oncology) sold 10,856 shares for an estimated $1,184,063
THOMAS TRAY (Principal Accounting Officer) has made 0 purchases and 4 sales selling 8,064 shares for an estimated $799,914.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$INCY Hedge Fund Activity

We have seen 421 institutional investors add shares of $INCY stock to their portfolio, and 413 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

WELLINGTON MANAGEMENT GROUP LLP added 2,526,758 shares (+341.7%) to their portfolio in Q1 2026, for an estimated $237,818,462
PACER ADVISORS, INC. removed 1,248,642 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $123,328,370
GOLDMAN SACHS GROUP INC added 1,067,757 shares (+83.2%) to their portfolio in Q1 2026, for an estimated $100,497,288
DODGE & COX removed 1,009,386 shares (-7.6%) from their portfolio in Q1 2026, for an estimated $95,003,410
AQR CAPITAL MANAGEMENT LLC removed 912,094 shares (-13.6%) from their portfolio in Q1 2026, for an estimated $85,846,287
MAN GROUP PLC removed 834,218 shares (-43.1%) from their portfolio in Q4 2025, for an estimated $82,395,711
SKANDINAVISKA ENSKILDA BANKEN AB (PUBL) removed 754,116 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $70,977,397

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$INCY Analyst Ratings

Wall Street analysts have issued reports on $INCY in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

HC Wainwright & Co. issued a "Buy" rating on 02/11/2026
TD Cowen issued a "Buy" rating on 01/13/2026

To track analyst ratings and price targets for $INCY, check out Quiver Quantitative's $INCY forecast page.

$INCY Price Targets

Multiple analysts have issued price targets for $INCY recently. We have seen 13 analysts offer price targets for $INCY in the last 6 months, with a median target of $101.0.

Here are some recent targets:

Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $140.0 on 06/09/2026
Jeffrey Walch from Bernstein set a target price of $99.0 on 05/22/2026
Stephen Willey from Stifel set a target price of $123.0 on 04/29/2026
Jay Olson from Oppenheimer set a target price of $90.0 on 04/29/2026
Ashwani Verma from UBS set a target price of $94.0 on 03/25/2026
Faisal Khurshid from Jefferies set a target price of $94.0 on 03/16/2026
Maneka Mirchandaney from Evercore ISI Group set a target price of $110.0 on 03/05/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.